Core Viewpoint - The company is focusing on the rapid growth of the recombinant human collagen market in China, which is projected to reach 585.7 billion yuan by 2025 and 2,193.8 billion yuan by 2030, with a compound annual growth rate of 44.93% [1]. Group 1: Market and Product Development - The recombinant human collagen products have gained wide market recognition due to their safety and effectiveness [1]. - The company has completed foundational research on various types of recombinant human collagen and is conducting application research in multiple medical fields [1]. - The company is investing in a production facility for injectable recombinant human collagen, specifically targeting type III collagen, which is expected to commence production this year [1]. Group 2: Brand and Sales Strategy - The company has established its own brands for medical devices and functional skincare products, including "Wei Yi Mei" and "Chong Yuan" [2]. - The company is prioritizing market expansion in Southeast Asia and has collaborated with L'Oréal Group for its raw material products [2]. - The company’s injectable recombinant type III human collagen gel has received approval and was globally launched at the Cannes Film Festival [2]. Group 3: International Expansion and Innovation - The company has obtained patents in the US, Europe, and Brazil, and is actively pursuing international market expansion [3]. - The company emphasizes the importance of both online and offline sales channels to achieve sustained growth [3].